{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:19:24Z","timestamp":1789604364939,"version":"build-2803163510"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The partial remission (PR) phase, a period experienced by most patients with type 1 diabetes (T1D) soon after diagnosis, is characterized by low insulin requirements and improved glycemic control. Given the great potential of this phase as a therapeutic window for immunotherapies because of its association with immunoregulatory mechanisms and \u03b2-cell protection, our objective was to find peripheral immunological biomarkers for its better characterization, monitoring, and prediction. The longitudinal follow-up of 17 pediatric patients with new-onset T1D over one year revealed that, during the PR phase, remitter patients show increased percentages of effector memory (EM) T lymphocytes, terminally differentiated EM T lymphocytes, and neutrophils in comparison to non-remitter patients. On the contrary, remitter patients showed lower percentages of na\u00efve T lymphocytes, regulatory T cells (T\n                    <jats:sub>REG<\/jats:sub>\n                    ), and dendritic cells (DCs). After a year of follow-up, these patients also presented increased levels of regulatory B cells and transitional T1 B lymphocytes. On the other hand, although none of the analyzed cytokines (IL-2, IL-6, TGF-\u03b21, IL-17A, and IL-10) could distinguish or predict remission, IL-17A was increased at T1D diagnosis in comparison to control subjects, and remitter patients tended to maintain lower levels of this cytokine than non-remitters. Therefore, these potential monitoring immunological biomarkers of PR support that this stage is governed by both metabolic and immunological factors and suggest immunoregulatory attempts during this phase. Furthermore, since the percentage of T\n                    <jats:sub>REG<\/jats:sub>\n                    , monocytes, and DCs, and the total daily insulin dose at diagnosis were found to be predictors of the PR phase, we next created an index-based predictive model comprising those immune cell percentages that could potentially predict remission at T1D onset. Although our preliminary study needs further validation, these candidate biomarkers could be useful for the immunological characterization of the PR phase, the stratification of patients with better disease prognosis, and a more personalized therapeutic management.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.825426","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T01:38:44Z","timestamp":1645580324000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 Diabetes"],"prefix":"10.3389","volume":"13","author":[{"given":"Laia","family":"Gomez-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Perna-Barrull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Caroz-Armayones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rodriguez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Valls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Corripio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vives-Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 Diabetes Mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4763-3","article-title":"Trends and Cyclical Variation in the Incidence of Childhood Type 1 Diabetes in 26 European Centres in the 25 Year Period 1989\u20132013: A Multicentre Prospective Registration Study","volume":"62","author":"Patterson","year":"2019","journal-title":"Diabetologia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nri2787","article-title":"Immune Cell Crosstalk in Type 1 Diabetes","volume":"10","author":"Lehuen","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S2213-8587(18)30112-8","article-title":"The Challenge of Modulating \u03b2-Cell Autoimmunity in Type 1 Diabetes","volume":"7","author":"Atkinson","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-8587(18)30109-8","article-title":"Antigen-Based Immune Modulation Therapy for Type 1 Diabetes: The Era of Precision Medicine","volume":"7","author":"Roep","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2012.05.005","article-title":"Immune Biomarkers in Immunotherapeutic Trials for Type 1 Diabetes: Cui Prodest","volume":"38","author":"Culina","year":"2012","journal-title":"Diabetes Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/cei.12085","article-title":"Progress in Immune-Based Therapies for Type 1 Diabetes","volume":"172","author":"von Herrath","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000479030","article-title":"Remission Phase in Paediatric Type 1 Diabetes: New Understanding and Emerging Biomarkers","volume":"88","author":"Fonolleda","year":"2017","journal-title":"Horm Res Paediatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-543X.2006.00155.x","article-title":"\u201cThe Honeymoon Phase\u201d in Children With Type 1 Diabetes Mellitus: Frequency, Duration, and Influential Factors","volume":"7","author":"Abdul-Rasoul","year":"2006","journal-title":"Pediatr Diabetes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jecr.2017.09.001","article-title":"Sustained Spontaneous Partial Remission in a Pediatric Patient With Type 1 Diabetes","volume":"6","author":"Murillo","year":"2017","journal-title":"J Clin Transl Endocrinol Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1207","article-title":"Complete Long-Term Recovery of -Cell Function in Autoimmune Type 1 Diabetes After Insulin Treatment","volume":"27","author":"Karges","year":"2004","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3207","article-title":"The Remission Phase in Type 1 Diabetes: Changing Epidemiology, Definitions, and Emerging Immuno-Metabolic Mechanisms","volume":"36","author":"Zhong","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176860","article-title":"A Predictive Model for Lack of Partial Clinical Remission in New-Onset Pediatric Type 1 Diabetes","volume":"12","author":"Marino","year":"2017","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2040202.101","article-title":"Features of Partial Remission in Children With Type 1 Diabetes Using the Insulin Dose-Adjusted A1c Definition and Risk Factors Associated With Nonremission","volume":"26","author":"Wong","year":"2021","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.600","article-title":"Immunological Mechanisms Associated With Long-Term Remission of Human Type 1 Diabetes","volume":"22","author":"Karges","year":"2006","journal-title":"Diabetes Metab Res Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00824","article-title":"The Remission Phase in Type 1 Diabetes: Role of Hyperglycemia Rectification in Immune Modulation","volume":"10","author":"Tang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136114","article-title":"CD4+CD25+CD127hi Cell Frequency Predicts Disease Progression in Type 1 Diabetes","volume":"6","author":"Narsale","year":"2021","journal-title":"JCI Insight"},{"key":"B18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clim.2016.04.012","article-title":"A Pilot Study Showing Associations Between Frequency of CD4+ Memory Cell Subsets at Diagnosis and Duration of Partial Remission in Type 1 Diabetes","author":"Moya","year":"2016","journal-title":"Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.trsl.2019.03.002","article-title":"Partial Remission and Early Stages of Pediatric Type 1 Diabetes Display Immunoregulatory Changes. A Pilot Study","volume":"210","author":"Villalba","year":"2019","journal-title":"Transl Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611522","article-title":"NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes","volume":"11","author":"Gomez-Mu\u00f1oz","year":"2021","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12671","article-title":"Immune Cell and Cytokine Patterns in Children With Type 1 Diabetes Mellitus Undergoing a Remission Phase: A Longitudinal Study","volume":"19","author":"Fitas","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.12.003","article-title":"Islet Antigen Specific IL-10+ Immune Responses But Not CD4+CD25+FoxP3+ Cells at Diagnosis Predict Glycemic Control in Type 1 Diabetes","volume":"127","author":"Sanda","year":"2008","journal-title":"Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1697","article-title":"Association of IL-1ra and Adiponectin With C-Peptide and Remission in Patients With Type 1 Diabetes","volume":"57","author":"Pfleger","year":"2008","journal-title":"Diabetes"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa130","article-title":"PD-1 and PD-L1 Expression in Peripheral CD4\/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes","volume":"105","author":"Li","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03172.x","article-title":"Association of Interferon-\u03b3 and Interleukin 10 Genotypes and Serum Levels With Partial Clinical Remission in Type 1 Diabetes","volume":"145","author":"Alizadeh","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02096.x","article-title":"Association of Immune Mediators at Diagnosis of Type 1 Diabetes With Later Clinical Remission","volume":"24","author":"Schloot","year":"2007","journal-title":"Diabetes Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04193.x","article-title":"Association of Adiponectin, Interleukin (IL)-1ra, Inducible Protein 10, IL-6 and Number of Islet Autoantibodies With Progression Patterns of Type 1 Diabetes the First Year After Diagnosis","volume":"161","author":"Kaas","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20142018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1157\/13123287","article-title":"Estudio Transversal Espa\u00f1ol De Crecimiento 2008. Parte II: Valores De Talla, Peso E \u00cdndice De Masa Corporal Desde El Nacimiento a La Talla Adulta","volume":"68","author":"Carrascosa Lezcano","year":"2008","journal-title":"Pediatr\u00eda"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1987","article-title":"New Definition for the Partial Remission Period in Children and Adolescents With Type 1 Diabetes","volume":"32","author":"Mortensen","year":"2009","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jama.2016.2240","article-title":"Biomarkers and Surrogate Endpoints: Developing Common Terminology and Definitions","volume":"315","author":"Robb","year":"2016","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jtbi.2015.07.032","article-title":"Continuum Model of T-Cell Avidity: Understanding Autoreactive and Regulatory T-Cell Responses in Type 1 Diabetes","volume":"383","author":"Jaberi-Douraki","year":"2015","journal-title":"J Theor Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2017-0100","article-title":"Markers Influencing the Presence of Partial Clinical Remission in Patients With Newly Diagnosed Type 1 Diabetes","volume":"30","author":"Pyziak","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3264","article-title":"From Immunohistological to Anatomical Alterations of Human Pancreas in Type 1 Diabetes: New Concepts on the Stage","volume":"36","author":"Nigi","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2249.2009.04053.x","article-title":"Gene Expression Profiles for the Human Pancreas and Purified Islets in Type 1 Diabetes: New Findings at Clinical Onset and in Long-Standing Diabetes","volume":"159","author":"Planas","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00630","article-title":"Pancreatic Alpha-Cells Contribute Together With Beta-Cells to CXCL10 Expression in Type 1 Diabetes","volume":"11","author":"Nigi","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/cei.13332","article-title":"Uibo R. A Study of 51 Subtypes of Peripheral Blood Immune Cells in Newly Diagnosed Young Type 1 Diabetes Patients","volume":"198","author":"Oras","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4067-4","article-title":"Islet Cell Hyperexpression of HLA Class I Antigens: A Defining Feature in Type 1 Diabetes","volume":"59","author":"Richardson","year":"2016","journal-title":"Diabetologia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1084\/jem.20111187","article-title":"Demonstration of Islet-Autoreactive CD8 T Cells in Insulitic Lesions From Recent Onset and Long-Term Type 1 Diabetes Patients","volume":"209","author":"Coppieters","year":"2012","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.cmet.2018.07.007","article-title":"Conventional and Neo-Antigenic Peptides Presented by \u03b2 Cells Are Targeted by Circulating Na\u00efve CD8+ T Cells in Type 1 Diabetic and Healthy Donors","volume":"28","author":"Gonzalez-Duque","year":"2018","journal-title":"Cell Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10991","article-title":"Type 1 Diabetes Vaccine Candidates Promote Human Foxp3+ Treg Induction in Humanized Mice","volume":"7","author":"Serr","year":"2016","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4377-1","article-title":"Regulatory T Cell Dysfunction in Type 1 Diabetes: What\u2019s Broken and How Can We Fix it","volume":"60","author":"Hull","year":"2017","journal-title":"Diabetologia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126595","article-title":"Autoreactive CD8+ T Cell Exhaustion Distinguishes Subjects With Slow Type 1 Diabetes Progression","volume":"130","author":"Wiedeman","year":"2020","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0090","article-title":"Expansion of Th17 Cells and Functional Defects in T Regulatory Cells Are Key Features of the Pancreatic Lymph Nodes in Patients With Type 1 Diabetes","volume":"60","author":"Ferraro","year":"2011","journal-title":"Diabetes"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12418","article-title":"Analyses of Regulatory CD4+ CD25+ FOXP3+ T Cells and Observations From Peripheral T Cell Subpopulation Markers During the Development of Type 1 Diabetes in Children","volume":"83","author":"Hamari","year":"2016","journal-title":"Scand J Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1248","article-title":"No Alterations in the Frequency of FOXP3+ Regulatory T-Cells in Type 1 Diabetes","volume":"56","author":"Brusko","year":"2007","journal-title":"Diabetes"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1615","article-title":"Differential Insulitic Profiles Determine the Extent of \u03b2-Cell Destruction and the Age at Onset of Type 1 Diabetes","volume":"65","author":"Leete","year":"2016","journal-title":"Diabetes"},{"key":"B48","article-title":"Innate Immunity in Type 1 Diabetes","volume":"11","author":"Diana","year":"2011","journal-title":"Discov Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12469","article-title":"Neutrophils in Type 1 Diabetes","volume":"7","author":"Huang","year":"2016","journal-title":"J Diabetes Investig"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12783","article-title":"NETosis-Associated Serum Biomarkers Are Reduced in Type 1 Diabetes in Association With Neutrophil Count","volume":"184","author":"Qin","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122146","article-title":"Abnormal Neutrophil Signature in the Blood and Pancreas of Presymptomatic and Symptomatic Type 1 Diabetes","volume":"3","author":"Vecchio","year":"2018","journal-title":"JCI Insight"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01958","article-title":"Expression, Role, and Regulation of Neutrophil Fc\u03b3 Receptors","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.04.012","article-title":"Neutrophil Diversity in Health and Disease","volume":"40","author":"Silvestre-Roig","year":"2019","journal-title":"Trends Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601629","article-title":"The Importance of Dendritic Cells in Maintaining Immune Tolerance","volume":"198","author":"Audiger","year":"2017","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02811","article-title":"Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential","volume":"10","author":"Rodriguez-Fernandez","year":"2019","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2460","article-title":"Altered Phenotype of Peripheral Blood Dendritic Cells in Pediatric Type 1 Diabetes","volume":"35","author":"Nieminen","year":"2012","journal-title":"Diabetes Care"},{"key":"B57","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00592-019-01427-1","article-title":"Changes in Innate and Adaptive Immunity Over the First Year After the Onset of Type 1 Diabetes","volume":"57","author":"Klocperk","year":"2020","journal-title":"Acta Diabetol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90586-3","article-title":"Defective Maturation and Function of Antigen-Presenting Cells in Type 1 Diabetes","volume":"345","author":"Jansen","year":"1995","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29380","article-title":"Brief Exposure to Hyperglycemia Activates Dendritic Cells In Vitro and In Vivo","volume":"235","author":"Thomas","year":"2020","journal-title":"J\u00a0Cell Physiol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12362","article-title":"Multi-Parametric Flow Cytometric and Genetic Investigation of the Peripheral B-Cell Compartment in Human Type 1 Diabetes","volume":"177","author":"Thompson","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611795","article-title":"Immunosuppressive Mechanisms of Regulatory B Cells","volume":"12","author":"Catal\u00e1n","year":"2021","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jaci.2015.09.014","article-title":"In-Depth Characterization of CD24 High CD38 High Transitional Human B Cells Reveals Different Regulatory Profiles","volume":"137","author":"Simon","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8935694","article-title":"Altered Regulatory B Cell Subsets in Children With Type 1 Diabetes Mellitus","volume":"2020","author":"El-Mokhtar","year":"2020","journal-title":"J Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/cei.13408","article-title":"Decrease in the Proportion of CD24 Hi CD38 Hi B Cells and Impairment of Their Regulatory Capacity in Type 1 Diabetes Patients","volume":"200","author":"Wang","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1643","article-title":"Peripheral and Islet Interleukin-17 Pathway Activation Characterizes Human Autoimmune Diabetes and Promotes Cytokine-Mediated -Cell Death","volume":"60","author":"Arif","year":"2011","journal-title":"Diabetes"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1152\/physiolgenomics.00173.2004","article-title":"Dynamic Interaction Between T Cell-Mediated \u03b2-Cell Damage and \u03b2-Cell Repair in the Run Up to Autoimmune Diabetes of the NOD Mouse","volume":"21","author":"Vukkadapu","year":"2005","journal-title":"Physiol Genomics"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-216085","article-title":"Evidence for a Cross-Talk Between Human Neutrophils and Th17 Cells","volume":"115","author":"Pelletier","year":"2010","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e93326","DOI":"10.1371\/journal.pone.0093326","article-title":"Predictive Models of Type 1 Diabetes Progression: Understanding T-Cell Cycles and Their Implications on Autoantibody Release","volume":"9","author":"Jaberi-Douraki","year":"2014","journal-title":"PloS One"},{"key":"B69","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1515\/jpem-2017-0100","article-title":"Influence of Age on Partial Clinical Remission Among Children With Newly Diagnosed Type 1 Diabetes","volume":"17","author":"Passanisi","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13044","article-title":"Frequency, Clinical Characteristics, and Determinants of Partial Remission in Type 1 Diabetes: Different Patterns in Children and Adults","volume":"12","author":"Zhong","year":"2020","journal-title":"J Diabetes"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12824","article-title":"Remission Phase in Children Diagnosed With Type 1 Diabetes in Years 2012 to 2013 in Silesia, Poland: An Observational Study","volume":"20","author":"Chobot","year":"2019","journal-title":"Pediatr Diabetes"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12413","article-title":"Factors Contributing to Partial Remission in Type 1 Diabetes: Analysis Based on the Insulin Dose-Adjusted HbA1c in 3657 Children and Adolescents From Germany and Austria","volume":"18","author":"Nagl","year":"2017","journal-title":"Pediatr Diabetes"},{"key":"B73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2249.2007.03475.x","article-title":"Dynamic Changes in CD4+ CD25+ High T Cell Apoptosis After the Diagnosis of Type 1 Diabetes","volume":"150","author":"Glisic-Milosavljevic","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21728","article-title":"Extended Immunophenotyping Reference Values in a Healthy Pediatric Population","volume":"96","author":"Garcia-Prat","year":"2019","journal-title":"Cytom Part B Clin Cytom"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0381-y","article-title":"A Clinically Meaningful Metric of Immune Age Derived From High-Dimensional Longitudinal Monitoring","volume":"25","author":"Alpert","year":"2019","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.07.003","article-title":"Lymphocyte Subsets in Healthy Children From Birth Through 18 Years of Age","volume":"112","author":"Shearer","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12208","article-title":"Partial Remission Definition: Validation Based on the Insulin Dose-Adjusted HbA1c (IDAA1C) in 129 Danish Children With New-Onset Type 1 Diabetes","volume":"15","author":"Max Andersen","year":"2014","journal-title":"Pediatr Diabetes"}],"updated-by":[{"DOI":"10.3389\/fimmu.2024.1439643","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.825426\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:01:30Z","timestamp":1718197290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.825426\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2022.825426"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.825426","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"article-number":"825426"}}